Alector and gsk announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

South san francisco, calif. and london, july 02, 2021 (globe newswire) -- alector, inc. (nasdaq: alec) and glaxosmithkline plc (lse/nyse: gsk), today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (al001 and al101) designed to elevate progranulin (pgrn) levels. pgrn is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments.
ALEC Ratings Summary
ALEC Quant Ranking